News | Ultrasound Women's Health | November 19, 2018

QView Medical Showcases QVCAD for ABUS Exams at RSNA 2018

Completes first joint installation of AI-based system for concurrent reading with Invenia ABUS from GE Healthcare

QView Medical Showcases QVCAD for ABUS Exams at RSNA 2018

November 19, 2018 – QView Medical will showcase QVCAD, the first U.S. Food and Drug Administration (FDA)-approved artificial intelligence (AI) computer-aided detection (CAD) system for concurrent reading of automated breast ultrasound (ABUS) exams, at the 104th Annual Radiological Society of North America (RSNA) meeting, Nov. 25-30, in Chicago. Being demonstrated for the first time since being approved, QVCAD reduces interpretation time of screening ABUS exams while maintaining diagnostic accuracy.  

In addition, QView successfully completed an installation of QVCAD at Northern Arizona Healthcare, the first joint installation with the Invenia ABUS system from GE Healthcare. Invenia ABUS is approved by the FDA for breast cancer screening as an adjunct to mammography for asymptomatic women with dense breasts. “We are excited to add the capability to offer ABUS as part of our comprehensive breast cancer screening program, which will help improve cancer detection for women with dense breasts. However, it was important that we implement with concurrent decision support from QVCAD to improve reading times while maintaining workflow and diagnostic confidence,” said Liz Palomino, MHA, RT, Northern Arizona Healthcare director of medical imaging, Flagstaff Medical Center, Sedona Medical Center, Verde Valley Medical Center and Verde Valley Medical Imaging Center.

Results from several clinical studies have shown that the addition of ABUS to screening mammography results in a significant increase in cancer detection in women with dense breasts. However, the interpretation of ABUS exams, with up to 2,000 images per case, is complex and time consuming, particularly for new users. According to results of a reader study published recently in the American Journal of Radiology, QVCAD reduced reader interpretation time by 33 percent while maintaining diagnostic accuracy.

Based on deep learning algorithms, the AI system is designed to detect suspicious areas of breast tissue with characteristics similar to breast lesions, and highlight suspicious area to distinguish potentially malignant lesions from normal breast tissue.  QVCAD is FDA-approved for use with ABUS systems and has received the CE mark for use with ABUS/ABVS systems.

To improve reader productivity, QVCAD provides synthetic 2-D images of all six volumetric datasets in a standard ABUS exam to provide an immediately visual overview of the case. The C-thru images, which are minimum intensity projections (MinIP), summarize each 3-D ABUS volume in a 2-D image. They bring attention to specific areas of interest by enhancement of radial spiculations and retraction patterns in coronal reconstructions, which are highly suggestive of breast cancer in ABUS. Users may select any CAD mark or area of interest on the C-thru image and the corresponding original ABUS images will be displayed, enabling users to efficiently review the entire ABUS case.

For more information: www.qviewmedical.com

Related Content

#SiemensHealthineers #Varian #Siemens The transformative combination accelerates the company’s impact on #global #healthcare and establishes a strong partner for #customers and #patients along the entire #cancer care continuum and for many of the most threatening #diseases
News | Radiology Business | April 15, 2021
April 15, 2021 — Siemens Healthineers AG an
Comparisons of high definition and standard definition infrared imaging for digital histopathology. Image courtesy of the Beckman Institute

Comparisons of high definition and standard definition infrared imaging for digital histopathology. Image courtesy of the Beckman Institute

News | Breast Imaging | April 14, 2021
April 14, 2021 — Detecting and analyzing breast cancer
A doctor reading #CXR scans using #SenseCare-Chest #DR Pro #diagnostic #software.

A doctor reading CXR scans using SenseCare-Chest DR Pro diagnostic software.

News | Artificial Intelligence | April 14, 2021
April 14, 2021 — SenseTime, a world-leading...
The U.S. Food and Drug Administration (#FDA) authorized marketing of #Medtronic's #GIGenius, the first device that uses #artificialintelligence (#AI) based on #machinelearning to assist #clinicians in detecting #lesions (such as #polyps or suspected tumors) in the #colon in real time during a c#olonoscopy.

The GI Genius intelligent endoscopy module works in real-time, automatically identifying and marking (with a green box) abnormalities consistent with colorectal polyps, including small flat polyps.

News | Artificial Intelligence | April 12, 2021
A 37-year-old woman developed a new, palpable left supraclavicular lymphadenopathy lump five days after her first dose of the Moderna COVID-19 vaccine in the left arm. On the day of vaccination, the patient was asymptomatic. This is an example of how the vaccine can mimic cancer and swollen lymph nodes. Image used with permission of RSNA.

A 37-year-old woman developed a new, palpable left supraclavicular lymphadenopathy lump five days after her first dose of the Moderna COVID-19 vaccine in the left arm. On the day of vaccination, the patient was asymptomatic. This is an example of how the vaccine can mimic cancer and swollen lymph nodes. Read more about this case study. Image used with permission of RSNA.

Feature | Coronavirus (COVID-19) | April 09, 2021 | By Dave Fornell, Editor
While the mass COVID-19 vaccinat
3-D mammography reduces the number of breast cancer cases diagnosed in the period between routine screenings, when compared with traditional mammography, according to a large study from Lund University in Sweden. The results are published in the journal Radiology.

Getty Images

News | Breast Imaging | April 09, 2021
April 9, 2021 — 3-D mammography reduces the number of breast cancer cases diagnosed in the period between routine scr
Varian announced it is collaborating with Google Cloud to build an advanced artificial intelligence (AI) based diagnostic platform to aid in the fight against cancer. Varian and Google Cloud AI embarked on a deployment journey, using Neural Architecture Search (NAS) technology via Google Cloud AI Platform, to create AI models for organ segmentation — a crucial and labor-intensive step in radiation oncology that can be a bottleneck in the cancer treatment clinical workflow.
News | Artificial Intelligence | April 08, 2021
April 8, 2021 — Varian announced it is collaborating with Google...
Mobidiag Oy, a privately held, commercial-stage Finnish-French developer of innovative molecular diagnostic tests and instrumentation, announced today that it has signed a definitive agreement to be acquired by Hologic, Inc., a global leader in women's health, for an enterprise value of approximately $795 million.  This includes a cash payment of approximately $714 million for Mobidiag’s equity, and net debt of approximately $81 million.
News | Women's Health | April 08, 2021
April 8, 2021 — Mobidiag Oy, a privately held, commercial-stage F